Q1FY22 Earnings Presentation

8 Strides 3 Sector Headwinds Industry headwinds impacts performance across markets in Q1FY22 Implications for Strides Mitigation Strategies 。 Major headwinds faced by the sector owing to current Covid-19 pandemic particularly for the regulated markets o Prescription rates trends below historical levels in the US 。 Significant fall in prescriptions rates down over ~20%, aggravated by lockdown in UK 。 Acute portfolio impacted severely 。 Continued drop in new product approvals for the industry due to travel restrictions and slowdown in inspections 。 Above dynamics has led to heightened competitive intensity to capture a higher wallet share for existing products, industry witnesses unprecedented price erosion o Rise in Covid-19 cases leads to intermittent lockdowns and restrictions across multiple geographies disrupting supply chain, increasing cost of operations 。 Witnessed double digit price erosion in our US portfolio with higher competitive intensity leading to significant drop in revenues 。 New product launches from Q4FY21 have witnessed steep price erosion in the US 。 Delays in products approvals impact new product launch cycles 。 Significant rise in Covid-19 cases during the second wave at all our manufacturing sites in India lead to operational disruptions and impacted supplies Failure to supply (FTS) cost pre-Covid in FY20 was <1% of US sales. The same has increased to ~4% due to Covid led supply disruptions 。 Logistics cost higher by US$4m YoY due to higher air shipments US Business 。 Strides announced acquisition of basket of ANDAs and manufacturing site at Chestnut Ridge, New York from Endo Pharmaceuticals 。 Acquired basket of products to deliver the following outcomes: 。 Adjusting for overlapping products, our portfolio of 100 approved products will more than double 。 Transaction immediately adds 20 commercial products to Strides portfolio 。 Mitigates delays in approvals due to Covid-19 induced travel restrictions and delay in inspections. and now provides a large basket of commercializable portfolio 。 Enabling 5-6 new launches from the combined portfolio each quarter for consistent growth o Adds new dosage capabilities including Controlled Substances, Hormones, Nasal Sprays, Gels 。 Significantly enhances our nascent modified release and liquids portfolio Middle of pyramid basket now expands 2x to over 100+ products having limited competition and superior margin 100+ TAA compliant products in the combined portfolio for government supplies Consolidating West Palm Beach operations with Chestnut Ridge site to optimize cost Other Regulated Markets 。 Continued R&D investments for portfolio building, focus on consistent product launches 。 Minimize stockout to drive higher order fulfillment rate for partnered business Other Initiatives 。 Initiatives in place to lower logistics cost and FTS in H2FY22 o Organization wide cost control programs to deliver operating leverage О R&D to focus on specialty portfolio and portfolio maximization

View entire presentation